Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury

Acta Pharmacologica Sinica

Volumn 32, Issue 5, 2011, Pages 601-610

  He, Min ^a   Cheng, Ni ^b   Gao, Wei Wei ^a   Zhang, Meng ^a   Zhang, Yue Yun ^a   Ye, Richard D ^b   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

anti inflammation; bleomycin; cytokines; formyl peptide receptor; lung injury; Quin C1

Indexed keywords

4 BUTOXY N [2 (4 METHOXYPHENYL) 4 OXO 1,4 DIHYDRO 2H QUINAZOLIN 3 YL]BENZAMIDE; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; BLEOMYCIN; COLLAGEN; FORMYL PEPTIDE RECEPTOR 2; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYPROLINE; INTERLEUKIN 1BETA; KERATINOCYTE DERIVED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; IN VIVO STUDY; LEUKOCYTE COUNT; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BLEOMYCIN; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION; LUNG INJURY; MALE; MICE; MICE, INBRED ICR; QUINAZOLINES; RECEPTORS, FORMYL PEPTIDE; TIME FACTORS;

EID: 79959769615     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.4     Document Type: Article

References (46)

1. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 2006; 17: 501-19. (Pubitemid 44793122)
2. Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 2005; 35: 2486-95.
3. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009; 61: 119-61.
4. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994; 180: 253-60. (Pubitemid 24181074)
5. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 141-62. (Pubitemid 41253472)
6. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006; 58: 463-87. (Pubitemid 44394909)
7. Schaldach CM, Riby J, Bjeldanes LF. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999; 38: 7594-600.
8. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010; 184: 2611-9.
9. Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, et al. A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol 2004; 66: 1213-22. (Pubitemid 39411061)
10. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB, et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999; 163: 6777-84.
11. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol 1974; 77: 185-97.
12. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33: 9-13. (Pubitemid 40961008)
13. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-60.
14. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992; 18: 29-43.
15. Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev 2008; 17: 151-6.
16. Waseda Y, Yasui M, Nishizawa Y, Inuzuka K, Takato H, Ichikawa Y, et al. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir Res 2008; 9: 43.
17. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-9. (Pubitemid 26142071)
18. Pua ZJ, Stonestreet BS, Cullen A, Shahsafaei A, Sadowska GB, Sunday ME. Histochemical analyses of altered fetal lung development following single vs multiple courses of antenatal steroids. J Histochem Cytochem 2005; 53: 1469-79.
19. Wang ZG, Ye RD. Characterization of two new members of the formyl peptide receptor gene family from 129S6 mice. Gene 2002; 299: 57-63. (Pubitemid 35379827)
20. Southgate EL, He RL, Gao JL, Murphy PM, Nanamori M, Ye RD. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol 2008; 181: 1429-37.
21. Cheever AW, Dunn MA, Dean DA, Duvall RH. Differences in hepatic fibrosis in ICR, C3H, and C57BL/6 mice infected with Schistosoma mansoni. Am J Trop Med Hyg 1983; 32: 1364-9. (Pubitemid 14207387)
22. Kanekal S, Fraiser L, Kehrer JP. Pharmacokinetics, metabolic activation, and lung toxicity of cyclophosphamide in C57/B16 and ICR mice. Toxicol Appl Pharmacol 1992; 114: 1-8.
23. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999; 1: 1349-65.
24. Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006; 3: 413-7. (Pubitemid 44033355)
25. Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. J Pharmacol Exp Ther 2000; 293: 82-90. (Pubitemid 30180926)
26. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, et al. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2006; 173: 1016-22.
27. Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 283: L103-12.
28. Yara S, Kawakami K, Kudeken N, Tohyama M, Teruya K, Chinen T, et al. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol 2001; 124: 77-85. (Pubitemid 32476937)
29. Hamaguchi Y, Nishizawa Y, Yasui M, Hasegawa M, Kaburagi Y, Komura K, et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol 2002; 161: 1607-18. (Pubitemid 35265521)
30. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999; 65: 187-95. (Pubitemid 29077011)
31. Okazaki T, Nakao A, Nakano H, Takahashi F, Takahashi K, Shimozato O, et al. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol 2001; 167: 1977-81. (Pubitemid 32747503)
32. Chen ES, Greenlee BM, Wills-Karp M, Moller DR. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001; 24: 545-55. (Pubitemid 32442761)
33. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002; 27: 419-27.
34. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-16. (Pubitemid 40385302)
35. Strieter RM, Gomperts BN, Keane MP. The role of cxc chemokines in pulmonary fibrosis. J Clin Invest 2007; 117: 549-56. (Pubitemid 46348509)
36. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/ CXCL10. Am J Respir Cell Mol Biol 2004; 31: 395-404. (Pubitemid 39330949)
37. O'Meara SJ, Rodgers K, Godson C. Lipoxins: update and impact of endogenous pro-resolution lipid mediators. Rev Physiol Biochem Pharmacol 2008; 160: 47-70.
38. Vaughn MW, Proske RJ, Haviland DL. Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. J Immunol 2002; 169: 3363-9. (Pubitemid 35013186)
39. Chen K, Le Y, Liu Y, Gong W, Ying G, Huang J, et al. A critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol 2010; 184: 3331-5.
40. Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 2000; 5: 831-40.
41. Bae YS, Park JC, He R, Ye RD, Kwak JY, Suh PG, et al. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met- CONH2 or lipoxin A4 in human neutrophils. Mol Pharmacol 2003; 64: 721-30. (Pubitemid 37048577)
42. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006; 12: 330-4. (Pubitemid 43355082)
43. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000; 164: 1663-7. (Pubitemid 30108713)
44. Romano M, Maddox JF, Serhan CN. Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: evidence for differential Ca2+ mobilization. J Immunol 1996; 157: 2149-54. (Pubitemid 126449694)
45. Burli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 2006; 16: 3713-8. (Pubitemid 44137222)
46. Martins V, Valenca SS, Farias-Filho FA, Molinaro R, Simoes RL, Ferreira TP, et al. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009; 182: 5374-81.